Thales Laser on Mars 2020 Mission: Three Days to Touchdown
16.2.2021 01:40:00 EET | Business Wire | Press release
On 18 February, the Perseverance rover — a key component of the Mars 2020 mission — will touch down on the Red Planet after a long seven-month voyage. SuperCam, one of seven strategic onboard instruments, is a powerful combination of technologies designed to analyse, characterise and select Martian rock samples. SuperCam is the result of close collaboration between Los Alamos National Laboratory (LANL) in the United States and the astrophysics and planetology research institute in France (IRAP, CNRS / CNES / Université Toulouse III - Paul Sabatier), with contributions from the University of Hawaii and the University of Valladolid in Spain. The Mast Unit, the French part of SuperCam located at the top of the rover’s mast, was designed and built by a consortium of French laboratories1 from CNRS, universities and entities under the scientific lead of the IRAP team and under the responsibility of CNES, the French space agency. The laser supplied by Thales is a key part of the Mast Unit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210215005423/en/
Credits: NASA
In 2012, Curiosity landed on Mars equipped with the first high-power laser to operate on the surface of another planet, a laser designed and developed by Thales for the ChemCam instrument. The ChemCam laser has been operating faultlessly for over eight years and has fired close to 855,000 shots to date as Curiosity has made its 24-kilometre trek across the surface of the Red Planet. Data from ChemCam has already helped to prove that conditions on Mars were once suitable for microbial life.
The SuperCam instrument, a new and more powerful version of ChemCam, is designed to take Mars exploration to a new level. Like ChemCam, the SuperCam laser will use an infrared beam to heat material to a temperature of around 10,000°C and vaporise it — a method called laser induced breakdown spectroscopy. Coupled with a special camera, this makes it possible to determine the chemical composition of Martian rock samples by measuring the colours of light in the plasma created.
Unlike ChemCam, however, the SuperCam laser can also emit a green laser beam, which will help determine the molecular composition of surface materials. This green beam excites the chemical bonds in samples and produces a different signal according to their various linked components. This analysis technique, known as Raman spectroscopy, will be tested for the first time on Mars and will enable scientists to detect any markers of life. The green laser will also be used to induce fluorescence in mineral and organic compounds, allowing scientists to determine their constituent components with greater accuracy.
“We’re proud to have provided NASA with the first two lasers to operate on Mars. The Mars 2020 mission is a decisive step forward in the study of the Red Planet and preparations for future expeditions. SuperCam, the ‘eyes’ of Perseverance, is the result of close collaboration between partners across the international scientific community. Thales's SuperCam laser delivers unrivalled performance and will enable Perseverance to perform its exploration mission throughout its time on the surface of Mars.” Christophe Salomon, Executive Vice President, Land and Air Systems
About Mars 2020
The goal of the Mars 2020 mission is to study the Red Planet’s surface, search for signs of past life, take rock and dust samples at selected sites and store them for retrieval by the future Mars Sample Return (MSR) mission, which will be conducted jointly with the European Space Agency. Thales Alenia Space is closely involved in the MSR mission.
The Mars 2020 mission is designed to gather the necessary knowledge and test the technologies that will be vital for future human expeditions to the Red Planet.
How to produce oxygen from the Martian atmosphere? What resources are available? Is there water beneath the surface, for example? How to improve landing techniques and characterise weather conditions, dust levels and other environmental conditions that could affect the life and work of future astronauts on Mars? These are just some of the questions the Perseverance mission will seek to answer.
About Thales lasers
For more than 35 years, Thales has been a world leader in design, development and manufacturing of high energy nanosecond lasers for industrial applications and the most powerful ultra-short Ti:Sa femtosecond laser systems for leading scientific applications with peak power up to 10 petawatts.
Thales provides the most reliable and easy-to-use products, a unique combination of technological expertise and robustness for implementation into industrial applications that require highest availability such as laser annealing, laser lift-off, laser shock peening and cutting of composites for various industries such as aerospace, microelectronics, flat panel displays and many others. Thales provides also a full range of services, which are optimized to support each customer.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
[1] The Irap ; the Laboratoire d’études spatiales et d’instrumentation en astrophysique (LESIA, Observatoire de Paris-PSL/CNRS/SU/Université de Paris) ; the Laboratoire d’astrophysique de Bordeaux (LAB, CNRS/Université de Bordeaux) ; the Laboratoire « atmosphères et observations spatiales » (LATMOS, CNRS/SU/UVSQ) ; l’Observatoire Midi-Pyrénées (OMP, CNRS/IRD/Météo-France/Université de Toulouse III – Paul Sabatier) ; the Institut d’astrophysique spatiale (IAS, CNRS/Université Paris-Saclay).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005423/en/
Contact information
PRESS
Thales, Media Relations
Group and Innovation
Alice Pruvot
+33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
Thales Alenia Space, Media Relations
Sandrine Bielecki
+33 (0)4 92 92 70 94
sandrine.bielecki@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom